Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Stoke Therapeutics (STOK) EBT (2022 - 2025)

Stoke Therapeutics (STOK) has 4 years of EBT data on record, last reported at -$39.6 million in Q3 2025.

  • For Q3 2025, EBT fell 49.93% year-over-year to -$39.6 million; the TTM value through Sep 2025 reached $40.4 million, up 138.26%, while the annual FY2024 figure was -$88.7 million, 15.38% up from the prior year.
  • EBT reached -$39.6 million in Q3 2025 per STOK's latest filing, down from -$23.5 million in the prior quarter.
  • Across five years, EBT topped out at $114.2 million in Q1 2025 and bottomed at -$39.6 million in Q3 2025.
  • Average EBT over 4 years is -$16.3 million, with a median of -$25.7 million recorded in 2024.
  • The widest YoY moves for EBT: up 532.84% in 2025, down 49.93% in 2025.
  • A 4-year view of EBT shows it stood at -$25.7 million in 2022, then dropped by 5.07% to -$27.0 million in 2023, then surged by 60.42% to -$10.7 million in 2024, then tumbled by 270.86% to -$39.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBT were -$39.6 million in Q3 2025, -$23.5 million in Q2 2025, and $114.2 million in Q1 2025.